Chronic dialysis has been performed on patients with kidney failure since the early 1960's. A dialyzer is a device for cleansing blood through hemodialysis by a process of diffusion and/or convection of waste products, dissolved solutes and fluid from the blood across a semi permeable membrane into a dialysis solution known as dialysate. A dialysis system is an assembly that includes the dialyzer and associated equipment to support the dialyzer, such a plumbing and pumps.
Diffusion is the principal mechanism in which dialysis removes waste products such as urea, creatinine, phosphate and uric acid, among others, from the blood. A differential between the chemical composition of the dialysate and the chemical composition of the blood causes the waste products to be drawn through the semi-permeable membrane from the blood into the dialysate. Ultrafiltration is a process in dialysis where fluid is caused to move across the membrane from the blood into the dialysate for the purpose of removing excess fluid from the patient's blood stream. Along with water, some solutes are also drawn across via convection rather than diffusion. Ultrafiltration is a result of a pressure differential between the blood compartment of the dialyzer and the dialysate compartment of the dialyzer where fluid will move from a higher pressure to a lower pressure. In some circumstances, by design or unintentionally, fluid in the dialysate compartment is higher than the blood compartment, causing fluid to move from the dialysate compartment into the blood compartment. This is commonly referred to as reverse ultrafiltration.
It would be convenient for a patient to be able to perform dialysis in his or her home. Unfortunately, current dialysis systems are large in size, making them generally unsuitable for use in a patient's home. Current dialysis systems are also energy-inefficient in that they use large amounts of energy and require enormous amounts of water for proper use. Although some home dialysis systems are available, they generally use complex flow-balancing technology that is relatively expensive to manufacture and most systems are designed with a system of solenoid valves that create high noise levels. As a result, most dialysis treatments are performed at dialysis centers.
In view of the foregoing, there is a need for improved dialysis systems that are smaller, more portable, consume less water and that provide precise control over a level of ultrafiltration. Disclosed are systems and methods for performing hemodialysis that include fluid handling systems and provide accurate control over the type and level of hemodialysis being performed. The system includes a first pump for pumping dialysate into a dialyzer and a second pump for pumping dialysate out of the dialyzer. The system also includes a third pump that provides improved control of a level of ultrafiltration, hemodiafiltration, or both, as described in detail below.
In one aspect, there is disclosed a method of performing dialysis, comprising: operating a first pump to pump dialysate at a first flow rate through a fluid inlet pathway into a dialyzer; operating a second pump to pump the dialysate through a fluid outlet pathway out of the dialyzer; operating a third pump to pump the dialysate through the fluid outlet pathway in cooperation with the second pump, wherein the second and third pumps cooperate to collectively achieve a second flow rate through the fluid outlet pathway from the dialyzer; and pumping blood through the dialyzer in communication with the dialysate such that the dialyzer dialyzes the blood.
In another aspect, there is disclosed a method of performing dialysis, comprising: providing a dialysis system having an inlet conduit through which fluid flows in an inward direction toward a dialyzer and an outlet conduit through which fluid flows in an outward direction from the dialyzer; pumping fluid through the inlet conduit using a first pump; pumping fluid through the outlet conduit using a second pump; and using a third pump to supplement the pumping of the second pump through the outlet conduit.
In another aspect, there is disclosed a dialysis system, comprising: a dialyzer having a blood flow pathway through which blood flows; a fluid inlet pathway configured to provide incoming fluid to the dialyzer; a fluid outlet pathway configured to receive outgoing fluid from the dialyzer; a first pump coupled to the fluid inlet pathway and configured to pump the fluid through the fluid inlet pathway toward the dialyzer; a second pump coupled to the fluid outlet pathway and configured to pump the fluid through the fluid outlet pathway away from the dialyzer; and a third pump coupled to the fluid outlet pathway, the third pump configured to work in cooperation with the second pump to achieve a desired flow rate of fluid to or from the blood flowing through the dialyzer.
Other features and advantages should be apparent from the following description of various embodiments, which illustrate, by way of example, the principles of the disclosed devices and methods.
In order to promote an understanding of the principals of the disclosure, reference is made to the drawings and the embodiments illustrated therein. Nevertheless, it will be understood that the drawings are illustrative and no limitation of the scope of the disclosure is thereby intended. Any such alterations and further modifications in the illustrated embodiments, and any such further applications of the principles of the disclosure as illustrated herein are contemplated as would normally occur to one of ordinary skill in the art.
Ultrafiltration is a process in dialysis where fluid is caused to move across a dialyzer membrane via diffusion from the blood into the dialysate for the purpose of removing excess fluid from the patient's blood stream. Along with water, some solutes are also drawn across the membrane via convection rather than diffusion. Ultrafiltration is a result of a pressure differential between the blood compartment and the dialysate compartment where fluid will move from a higher pressure to a lower pressure.
In some circumstances, by design or unintentional, fluid in the dialysate compartment is higher than the blood compartment causing fluid to move from the dialysate compartment into the blood compartment. This is commonly referred to as reverse ultrafiltration. In hemodiafiltration a high level of ultrafiltration is created, greater than the amount required to remove fluid from the patient's blood, for the purpose of increasing convective solute transport across the membrane. The amount of fluid in excess of what is required to be removed from the patient's blood must therefore be returned to the blood stream in order to avoid an adverse blood reaction. This is accomplished by intentionally increasing the pressure in the dialysate compartment of the dialyzer to cause the appropriate amount of reverse ultrafiltration. This process of ultrafiltration alternating with reverse ultrafiltration is often referred to as “push-pull hemodiafiltration”. This is a significant improvement over more common methods of hemodiafiltration where sterile fluid is administered to the patient in a location outside of the dialyzer.
The dialysis system includes a dialyzer 105 that is fluidly connected to a source 110 of fluid (such as dialysate) and also to a source 115 of blood to be dialyzed. The source 115 of blood may be a patient. The source 110 of fluid may be a dialysate preparation system that prepares dialysate for use in the dialysis system. The dialysate preparation system may include a water purification system that purifies water pursuant to systems and methods described in U.S. patent application Ser. No. 12/795,382, entitled “Fluid Purification System”, filed Jun. 7, 2010, now U.S. Pat. No. 8,501,009, and which is incorporated by reference in its entirety. In addition, the dialyzer 105 may be at least partially configured with microfluidic pathways as described in U.S. patent application Ser. No. 12/795,371 entitled “Microfluidic Devices”, filed Jun. 7, 2010, which claims priority to U.S. Provisional Application No. 61/220,117, filed Jun. 24, 2009, which applications are incorporated by reference in their entirety. U.S. patent application Ser. No. 12/795,444 entitled “Dialysis System”, filed Jun. 7, 2010, now U.S. Pat. No. 8,801,922, is also incorporated by reference in its entirety. Dialysate flows into the dialyzer 105 through a fluid inlet 120 and out of the dialyzer 105 through a fluid outlet 125. Blood flows through the dialyzer 105 via a blood flow pathway 124 that includes a blood inlet 130 into the dialyzer 105 and a blood outlet 133 out of the dialyzer. From the dialyzer 105, the blood flows back to the patient. The dialyzer 105 is described in more detail below.
The dialysis system includes plumbing that forms a plurality of fluid flow pathways, which may be any type of conduit through which a fluid such as dialysate may flow. The fluid flow pathways include an inlet pathway 132 through which a fluid such as unused dialysate flows from the source 110 toward and into the dialyzer 105. At least a first pump 135 is positioned along or in communication with the inlet pathway 132 for pumping the fluid toward the dialyzer 105 at a desired flow rate. One or more sensors S may be coupled to the fluid flow pathway for sensing one or more characteristics of the incoming fluid, such as pressure, flow rate, temperature, conductivity, etc. In addition, one or more sample ports P may be coupled to the fluid flow pathways that provide access to fluid flowing through the piping.
The fluid flow pathways further include an outlet pathway 137 through which used dialysate flows out of the dialyzer 105 toward one or more drains 140. In some embodiments, the dialysate exiting the dialyzer may be used to pre-heat other incoming fluids in the system, such as the water stream entering the heat exchange and purification system, before reaching the drain 140. The outlet pathway 137 bifurcates into two or more outlet pathways including a main outlet pathway 137a and a secondary outlet pathway 1137b. At least a second pump 155 is positioned along or in communication with the main outlet pathway 137a for pumping the dialysate out of and away from the dialyzer 105 through the main outlet pathway 137a.
A third pump 160 is positioned along or in communication with the secondary outlet pathway 137b. The third pump 160 can be used to augment fluid flow through the fluid flow pathways such as to selectively achieve differentials in flow rates between the inflow pathway 132 and the outflow pathway 132 pursuant to achieving various types of dialysis, including hemodialysis, ultrafiltration, and hemodiafiltration, as described more fully below. The third pump pumps dialysate through the fluid flow pathways when the system is in dialysis mode. The third pump may also pump another fluid, such as water or disinfectant, when the system is in a different mode, such as in a calibration mode or in a cleaning mode. The third pump 160 can also be used to calibrate flow rates between the first pump 135 and the second pump 155, as described more fully below.
In another embodiment, shown in
Various types of pumps may be used for the first, second and third pumps. In an embodiment, the pumps are nutating pumps. On other embodiments, the pumps could be rotary lobe pumps, progressing cavity pumps, rotary gear pumps, piston pumps, diaphragm pumps, screw pumps, gear pumps, hydraulic pumps, vane pumps, regenerative (peripheral) pumps, or peristaltic pumps, or any combination thereof. Other types of pumps can also be used. The first pump 135 and the second pump 155 may be driven by a common shaft to ensure synchrony of the pump strokes and the volume of fluid pumped. It is understood that first pump 135 and the second pump 155 may also be fully independent from each other.
As mentioned, any of a variety of fluid conduits may be used to form the fluid flow pathways. In an embodiment, at least a portion of the fluid flow pathway is formed of piping having an inside diameter from ⅛ inch to ½ inch. The flow rate in the piping could range between about 50 ml/min to about 1,000 ml/min. In an embodiment, the flow rate is in the range of between about 100 ml/min and about 300 ml/min.
With reference again to
A first valve 170 is positioned at the junction between the inlet pathway 132 and the bypass pathway 165. A second valve 175 is positioned at the junction between the bypass pathway 165 and the outlet pathway 137. The first valve 170 and second valve 175 are three-way valves, such as solenoid valves, that can be used to selectively regulate fluid flow through the fluid flow pathways. That is, the first valve 170 can be set to either of two or more settings including (1) a dialysis setting wherein the first valve directs all incoming fluid along the inlet pathway 132 toward the dialyzer 105 (as represented by arrow A in
The second valve 175 can also be set to either of two settings including (1) a bypass setting wherein the second valve 175 directs incoming fluid from the bypass pathway 165 into the outlet pathway 137 (as represented by arrow C in
The arrangement of the various components of the dialysis system shown in
Dialyzer and Various Forms of Dialysis
When flowing through the dialyzer 105, the blood and the dialysate may flow in a counter-flow configuration wherein blood flows through the blood flow pathway 205 in one direction and the dialysate flows through the dialysate flow pathway 210 in the opposite direction. The dialyzer 105 is described in the context of having a counter-flow configuration although a cross-flow configuration may also be used. As the blood and water flow along the membrane 215, hemodialysis occurs. That is, waste solutes move across the semipermeable membrane 215 from the blood into the dialysate via diffusion as a result of the differential of solute concentration between the blood and the dialysate. The flow of the blood and dialysate, which may be counter-, cross- or concurrent-flow, maintains the concentration gradient of solutes between the blood and dialysate, which helps to remove more urea and creatinine from the blood. The concentrations of solutes (for example potassium, phosphorus, and urea) may be undesirably high in the blood, but low or absent in the dialysate and constant replacement of the dialysate ensures that the concentration of undesired solutes is kept low on the dialysate side of the membrane. The dialysate has levels of minerals like potassium and calcium that are similar to their natural concentration in healthy blood. For another solute, bicarbonate, the dialysate level is set at a slightly higher level than in normal blood, to encourage diffusion of bicarbonate into the blood, to maintain a patient's CO2 level, and act as a pH buffer to neutralize the metabolic acidosis that is often present in these patients.
The dialyzer 105 is also configured to perform ultrafiltration wherein a pressure differential across the membrane 215 results in fluid and dissolved solutes passing across the membrane 215 from the blood to the dialysate.
The dialyzer 105 is also configured to perform hemodiafiltration wherein solute movement across the semipermeable membrane 215 is governed by convection rather than by diffusion. A positive hydrostatic pressure differential between the blood flow pathway 205 and the dialysate flow pathway 210 drives water and solutes across the semipermeable membrane 215 from the blood flow pathway to the fluid flow pathway. Solutes of both small and large molecules get dragged through the semipermeable membrane 215 along with the fluid. In a typical hemodiafiltration procedure, the direction of water and solute movement is oscillated between moving water and solutes from the blood into the dialysate and moving water and solutes from the dialysate into the blood. Over a predetermined span of time, there is a net zero loss and zero net gain of fluid from the blood into the dialysate. However, during discrete time periods within that span of time, there can be a net loss of fluid from the blood into the dialysate and a net gain of fluid into the blood from the dialysate.
Operation of Pumps to Achieve Hemodialysis without Ultrafiltration
With reference again to
In an embodiment, the system performs a hemodialysis procedure utilizing all three pumps in an active state substantially continuously throughout the hemodialysis procedure. The system adjusts the pump rate of the third pump 160 to achieve a desired balance of equal flow rates between the inlet pathway 132 and the outlet pathway 137. In this embodiment, the first pump 135, second pump 155, and third pump 160 are all active throughout the hemodialysis procedure with the first and second pumps operating at different pump rates and the third pump operating at a pump rate that achieves a balanced flow rate between the inlet pathway 132 and the outlet pathway 136. The third pump is typically operated at a pump rate that is equal to the differential between the pump rate of the first pump and the pump rate of the second pump. In this manner, the second and third pumps collectively achieve a flow rate through the outlet pathway 137 that is equal to the flow rate through the inlet pathway 132.
For example, to achieve a desired flow rate of, for example, 100 ml/min through the dialyzer, the first pump 135 is set to provide a flow rate of 100 ml/min through the inlet pathway 132 and the second pump 155 is deliberately set out of balance with the first pump 135, to provide, for example, a flow rate of only 80 ml/min. This would provide a flow rate differential of 20 ml/min between the first pump and the second pump. The pump rate of third pump 160 is set to provide a flow rate of 20 ml/min, which is equal to the differential between the flow rates of the first and second pumps. In this manner, the second pump 155 and the third pump 160 collectively achieve a flow rate of 100 ml/min through the outlet pathway 137 which is equal to the flow rate of through the inlet pathway 132 such that the flow rates are balanced across the dialyzer. Under such conditions, waste solutes move across the dialyzer's semipermeable membrane from the blood stream into the dialysate via diffusion to perform hemodialysis.
The flow rates through the inlet pathway 132 and the outlet pathway 137 may be measured using one or more of the sensors S. In an embodiment, the sensors are flow rate sensors that directly measure flow rates through the inlet pathway 132 and outlet pathway 137. In another embodiment, the sensors are pressure sensors that provide indications as to the fluid pressure within the inlet pathway 132 and the fluid pressure within the outlet pathway 137. Fluid pressure is a function of the flow rate through the flow pathways and therefore provides an indirect measurement of flow rate. Where the fluid pressure in the inlet pathway 132 is equal to the fluid pressure in the outlet pathway 137, this is an indication that the flow rates are balanced between the inlet pathway and outlet pathway. Where the fluid pressure in the inlet pathway 132 is less than the fluid pressure through the outlet pathway 137, this is an indication that the flow rate through the inlet pathway 132 is less than the flow rate through the outlet pathway 137. Where the fluid pressure in the inlet pathway 132 is greater than the fluid pressure through the outlet pathway 137, this is an indication that the flow rate through the inlet pathway 132 is greater than the flow rate through the outlet pathway 137. The system of fluid pathways may include one or more damping mechanisms for dampening any extreme fluctuations in pressure within the fluid pathways.
In the latter two situations, the pump rate of the third pump 160 may be adjusted in response to a pressure differential between the inlet and outlet pathways such as in a calibration procedure, to achieve a balanced flow rate between the inlet pathway 132 and outlet pathway 137. The calibration procedure may optionally be performed with the system in a calibration mode such that the first and second valves are set to cause fluid to flow through the bypass pathway 165 and bypass the dialyzer 105, as represented in
In another embodiment, a balanced flow rate between the inlet pathway 132 and the outlet pathway 137 is achieved in theory at least by the first pump 135 and the second pump 155 operating at the same pump rate to achieve equal flow rates through the inlet pathway 132 and outlet pathway 137. Although it is theoretically possible to match the flow rates of the first pump 135 and the second pump 137, various factors may result in the actual fluid flow rate in the inlet pathway 132 differing from the actual fluid flow rate in the outlet pathway 137. The factors may include trapped air, hardware wear, and fluid leakage, which can cause the flow rates of the first and second pumps to diverge over time from a preset or desired value. Typical technologies in dialysis systems are unable to correct the flow balance for these types of factors.
Thus, there may come a time when a balanced flow rate cannot easily be achieved through use of the first and second pumps alone, and thus when there exists a need for correction to equalize the flow rates between the inlet pathway 132 and outlet pathway 137. Where the fluid flow rates are different, the third pump 160 can be used to correct the differing flow rates by being activated to pump fluid through the secondary outlet pathway 1137b at a rate that is equal to the delta between the fluid flow rate through the inlet pathway 132 and the fluid flow rate through the outlet pathway 137. The system is preferably configured such that the first pump 135 is prevented from pumping less fluid than the second pump 155 such that the first pump 135 always pumps at a higher rate than the second pump 155. The system preferably includes a control system that detects a condition where the first pump 135 inadvertently pumps at a slower rate than the second pump 155 and sets off an alarm or moves the system out of dialysis mode if such a situation occurs.
According to a flow rate correction process, the sensors S (
As mentioned, the sensors S may be communicatively coupled to a control system and to the three pumps in a closed loop system. The control system includes hardware and/or software that automatically activates and/or deactivates the third pump 160 or adjusts the pump rate of the third pump 160 as needed in response to differences in detected flow rates from predetermined values or from each other, to equalize the flow rates between the inlet pathway 132 and outlet pathway 137. It should be appreciated that other measurements, such as fluid pressure in the inlet and outlet pathways, may be used to indirectly calculate the flow rates rather than directly measuring the flow rates. In this regard, the fluid pressures within the inlet pathway and the outlet pathway may be measured for any detectable change in pressure from a predetermined value or from each other. The flow pathways may be adapted to be essentially non-compliant so that a small difference in the flow rates of the first pump 135 and the second pump 155 will cause a rapid pressure change either negative or positive in magnitude.
The system may initially and/or periodically run in a calibration mode (sometimes also referred to as a UF checking mode) wherein a fluid (which may or may not be dialysate) is flowed through the flow pathways with the first valve 170 and second valve 137 set to the “bypass setting” such that fluid flowing through the system bypasses the dialyzer 105 via the bypass pathway 165.
In the other embodiment, the first pump 135 and second pump 155 are initially set to achieve equal flow rates without necessarily requiring the assistance of the third pump 160, which is initially inactive. The sensors S in the flow pathway are then used to measure the fluid flow rate through the inlet pathway and the fluid flow rate through the outlet pathway. Where the fluid flow rates are equal, the third pump 160 remains inactive. However, where the fluid flow rates are not equal, the third pump 160 is run at a rate that compensates for the discrepancy in flow rates between the inlet pathway 132 and outlet pathway 137. As mentioned, the third pump 160 may operate in a closed-loop relationship with the flow rate sensors and/or the pressure sensors.
After the calibration procedure is completed, the valves 170 and 175 may be set to the “dialysis setting” such that fluid flows from the source 110, through the inlet pathway 132, into the dialyzer 105, out of the dialyzer, and into the outlet pathway 137 from the dialyzer 105. When configured as such, the system can be used for dialysis by flowing dialysate into and out of the dialyzer 105 via the inlet and outlet pathways, and by also by flowing blood into and out of the dialyzer via the blood flow pathway 124. During dialysis, the previously described calibration procedure may be periodically repeated, such as at predetermined intervals, to ensure that the flow rates of the inlet and outlet pathways remain within desired ranges.
In an embodiment, calibration is run only at the beginning of a dialysis session. In a more preferred embodiment, calibration is run periodically during the dialysis session, to ensure that the desired flow balance is maintained throughout the session. The control system can cycle the valves 170 and 175 controlling incoming flow stream between the dialysis setting and the bypass setting and run the calibration steps without additional interruptions to the dialysis session. During the calibration process, when the dialysate fluid bypasses the dialyzer 105, dialysis of the blood that passes through the dialyzer during that period of time is unhampered due to no fresh dialysate being provided to the dialyzer 105, though the blood may cool slightly. As long as the calibration step can be conducted over a relatively short period of time relative to the time between calibrations, the calibration has no material effect on the quality of dialysis being provided to the patient. In an embodiment, the dialysis system can be cycled between calibration for one minute followed by 60 minutes of dialysate being delivered through the dialyzer. In another embodiment, the dialysis system can be cycled between calibration for 30 seconds followed by 120 minutes of dialysate being delivered through the dialyzer. Various different cycle times between calibration and dialysis may be chosen based on how frequently the system's calibration is to be verified and/or adjusted. If no adjustment to any of the pumps is necessary during calibration, the calibration step may be concluded in a much shorter period of time than 30-seconds, for example 5-10 seconds.
Operation of Pumps to Achieve Ultrafiltration
The dialysis system achieves ultrafiltration in the situation where the flow rate through the inlet pathway 132 differs from the flow rate through the outlet pathway 137 such that there is an unbalanced flow rate across the dialyzer. Where the flow rate through the outlet pathway 137 is greater than the flow rate through the inlet pathway 132, the dialyzer 105 pulls fluid from the blood across the semipermeable membrane by a convective process in order to compensate for the unbalanced flow rate. In an embodiment, the system utilizes all three pumps substantially continuously throughout the procedure and the pump rate of the third pump 160 is adjusted to achieve a desired flow rate differential between the inlet pathway 132 and the outlet pathway 137 to perform ultrafiltration. That is, the first pump 135, second pump 155, and third pump 160 are all active with the first and second pumps operating at different pump rates. The third pump is then operated at a pump rate that intentionally achieves a desired imbalance of flow rates between the inlet pathway 132 and the outlet pathway 136 sufficient to cause ultrafiltration.
For example, to achieve the removal of fluid at a rate 10 ml/min from the blood stream, the first pump 135 is set to provide a flow rate of 100 ml/min through the inlet pathway 132 and the second pump 155 is deliberately set out of balance with the first pump 135, to provide, for example, a flow rate of only 80 ml/min. The third pump 160 is then set to provide a flow rate of 30 ml/min such that the second and third pumps collectively provide a flow rate of 110 ml/min through the outlet pathway 137. With a flow rate of 100 ml/min through the inlet pathway 132 and a flow rate of 110 ml/min through the outlet pathway, the dialyzer 105 compensates for the 10 ml/min flow rate differential by transferring 10 ml/min of fluid from the blood stream into the dialysate.
In another example, to achieve the addition of fluid at a flow rate of 10 ml/min into the blood stream, the first pump 135 is set to provide a flow rate of 100 ml/min through the inlet pathway 132 and the second pump 155 is again deliberately set out of balance with the first pump 135, to provide, for example, a flow rate of only 80 ml/min. The third pump 160 is then set to provide a flow rate of only 10 ml/min such that the second and third pumps collectively provide a flow rate of 90 ml/min through the outlet pathway 137. With a flow rate of 100 ml/min through the inlet pathway 132 and a flow rate of 90 ml/min through the outlet pathway, there is a transfer of 10 ml/min from the dialysate into the blood stream in order to compensate for the flow rate differential. It should be appreciated that the flow rate values in the preceding examples and following examples are only for purpose of example and that the actual flow rates as well as the relative flow rates can vary to achieve a desired level of ultrafiltration or reverse ultrafiltration.
The speed of the third pump 160 can be varied to selectively vary an amount of ultrafiltration. For example, if it is determined that the ultrafiltration is greater than desired when pulling fluid out of the blood, for example, the pump speed of the third pump 160 can be slowed down, reducing the amount of extra fluid that the third pump 160 draws out of the dialyzer. Where the ultrafiltration is not great enough when compared against a desired predetermined value, the pump speed of the third pump 160 may be increased in the case where fluid is being pulled out of the blood into the dialysate, for example, to draw an even greater amount of fluid out of the dialyzer and, hence, the blood.
In another embodiment, the third pump 160 may be coupled to a source of fluid such that the third pump 160 outputs extra fluid into the flow pathway via the secondary outlet pathway 137b, such as in the embodiment of
Operation of Pumps to Achieve Hemodiafiltration
The dialysis system is configured to achieve hemodiafiltration by oscillating the speed of the third pump between (1) a first speed such that the second and third pump collectively achieve a flow rate through the outlet pathway that is greater than the flow rate through the inlet pathway; and (2) a second speed such that the second and third pump collectively achieve a flow rate through the outlet pathway that is less than the flow rate through the inlet pathway. In this manner, the third pump 160 can be used to intermittently alternate the flow rate differential between a state where the dialyzer 105 pulls fluid from the blood stream into the dialysate and a state where the dialyzer 105 pushes fluid from the dialysate into the blood stream. Over a predetermined span of time, there should be a zero net loss (or substantially a zero net loss) of fluid from the blood and a zero net gain (or substantially a zero net gain) of fluid into the blood for the process of hemodiafiltration. However, during that span of time, the dialyzer 105 periodically transfers fluid into the blood from the dialysate and periodically transfers fluid out of the blood into the dialysate. If ultrafiltration is desired to be performed at the same time as the hemodiafiltration, then the pumps can be operated in such a way so that in addition to the cycling of fluid into and out of the blood over time, there also occurs a net gain or loss of fluid to or from the blood over a predetermined span of time.
For example over an exemplary time span of ten minutes, the first pump 135 is set to provide a flow rate of 100 ml/min through the inlet pathway 132 and the second pump 155 is again deliberately set out of balance with the first pump 135, to provide, for example, a flow rate of only 80 ml/min. The speed of pump 160 can be cycled between a rate of 10 ml/min for a period of 30 seconds and 30 ml/min for a period of 30 seconds. During the periods when the speed of the third pump 160 is at a rate of 10 ml/min, the total flow rate through the outlet pathway 137 is 90 ml/min with the flow rate through the inlet pathway 132 at 100 ml/min, resulting in an unbalanced flow rate that causes the dialyzer 105 to transfer 10 ml/min of fluid into the blood stream. During the periods when the speed of the third pump 160 is at a rate of 30 ml/min, the total flow rate through the outlet pathway 137 is 110 ml/min with the flow rate through the inlet pathway 132 at 100 ml/min, resulting in an unbalanced flow rate that causes the dialyzer 105 to transfer 10 ml/min of fluid from the blood stream into dialysate. Over the span of ten minutes with alternating periods of 30 seconds as described above, there is a net balanced flow rate of 100 ml/min across the dialyzer without any net addition or subtraction of fluid from the blood. This serves the purpose of passing fluid to the blood across the membrane and then fluid from the blood to the dialysate across the membrane to achieve hemodiafiltration of the blood and increases the removal of large-molecular waste products that would not otherwise be effectively dialyzed. In this way, operation of the three or more-pump system can achieve all of hemodialysis, ultrafiltration and hemodiafiltration through how the speeds of the first, second, and third pumps are controlled. This type of operation has heretofore not been possible in other dialysis systems.
In another embodiment, shown in
Between dialysis treatments, the flow pathways may be rinsed and/or disinfected. A rinse fluid, such as, but not limited to disinfectant solution and water, is routed through the flow pathways while the valves are in the bypass setting. During rinse mode, the third pump 160 may or may not be operated with the first pump 135 and second pump 155 to achieve fluid flow through the system.
Control of Flow Rates Using Pulsatile Pumps
In embodiments wherein the flow through flow pathways has a pulsatile nature, such as might be produced by certain types of pumps, the inherently high sensitivity of the methods described above might provide a challenge for controlling the flow rate as the small diameter and largely non-compliant flow pathways coupled with the pulsatile nature of the flow may make it difficult to measure pressures and pressure change rates sufficient to control the flow during dialysis.
In an embodiment, the pulsatile pressure signals present in a pulsatile flow configuration may be filtered out using appropriate signal conditioning. But the small volume and rigid flow pathways might cause too rapid of a pressure shift, quickly driving the pressure magnitude beyond the range of the pressure sensors. This may be particularly true for large, temporary mismatches associated with air being present in the flow pathways.
When the dialysis system is performing hemodialysis, the control valve 535 may be closed restricting the flow of the non-compliant fluid 545 to the second chamber 520 creating a substantially non-compliant flow circuit as the compliant diaphragm 510 is restricted from complying (elastically deforming) against the now relatively rigid non-compliant fluid 545.
During calibration of the dialysis system, the control valve 535 may be opened, allowing the non-compliant fluid 545 to react with the gas 550 in the air plenum in reaction to pressure transients of the fluid in the pathway acting against the diaphragm 510. The diaphragm 510 moves in response to the pressure change and the gas 550 in the air plenum tends to moderate and smooth the pressure changes, allowing for a more precise pressure detection during calibration for flow compensation by the third pump 160.
During hemodialysis operation of the system, the control valve 535 is opened, allowing the flow of non-compliant fluid 640 to flow into the second chamber 615 and against the diaphragm 510 which restricts the movement of the diaphragm 510 and therefore creates a substantially non-compliant flow circuit. During calibration of the system, the control valve 535 is closed, restricting the flow of the non-compliant fluid 640 into the second chamber 615 with the non-compliant fluid 640 left in the second chamber 615 free to flow to the drain. Without the flow of non-compliant fluid 640 reacting against the diaphragm 510 and the remaining fluid 640 in the second chamber 615 free to drain, the fluid can react against the diaphragm 510 unconstrained by the non-compliant fluid 640. The diaphragm 510 elastically moves in response to any pressure change in the flow circuit moderating and smoothing the pressure change, allowing for a more precise pressure detection in the flow pathways for flow compensation by the third pump 160.
It is appreciated that the compliance control devices 500 and 600, such as provided in
While this specification contains many specifics, these should not be construed as limitations on the scope of an invention that is claimed or of what may be claimed, but rather as descriptions of features specific to particular embodiments. Certain features that are described in this specification in the context of separate embodiments can also be implemented in combination in a single embodiment. Conversely, various features that are described in the context of a single embodiment can also be implemented in multiple embodiments separately or in any suitable sub-combination. Moreover, although features may be described above as acting in certain combinations and even initially claimed as such, one or more features from a claimed combination can in some cases be excised from the combination, and the claimed combination may be directed to a sub-combination or a variation of a sub-combination. Similarly, while operations are depicted in the drawings in a particular order, this should not be understood as requiring that such operations be performed in the particular order shown or in sequential order, or that all illustrated operations be performed, to achieve desirable results.
Although embodiments of various methods and devices are described herein in detail with reference to certain versions, it should be appreciated that other versions, embodiments, methods of use, and combinations thereof are also possible. Therefore the spirit and scope of the appended claims should not be limited to the description of the embodiments contained herein.
This application is a continuation of U.S. application Ser. No. 14/305,952, filed Jun. 16, 2014, which is a continuation of U.S. application Ser. No. 12/795,498, filed Jun. 7, 2010, now U.S. Pat. No. 8,753,515, that in turn claims priority to U.S. Provisional Application No. 61/267,043, filed Dec. 5, 2009. Priority of the filing date of Dec. 5, 2009, is hereby claimed, and the disclosures of the aforementioned patent applications are hereby incorporated by reference, each in its entirety.
Number | Name | Date | Kind |
---|---|---|---|
3356360 | Ward | Dec 1967 | A |
3695445 | Esmond | Oct 1972 | A |
3710237 | Watson et al. | Jan 1973 | A |
3762032 | Bowling et al. | Oct 1973 | A |
3809309 | Batista | May 1974 | A |
3827563 | Boe et al. | Aug 1974 | A |
3965008 | Dawson | Jun 1976 | A |
4080295 | Riede | Mar 1978 | A |
4089456 | Toppen et al. | May 1978 | A |
4100068 | Jordan et al. | Jul 1978 | A |
4110220 | Lavender | Aug 1978 | A |
4115273 | Winstead | Sep 1978 | A |
4155157 | Gersbacher | May 1979 | A |
4172033 | Willock | Oct 1979 | A |
4194014 | Hermans et al. | Mar 1980 | A |
4204628 | Houston et al. | May 1980 | A |
4209391 | Lipps | Jun 1980 | A |
4229299 | Savitz et al. | Oct 1980 | A |
4231366 | Schael | Nov 1980 | A |
4267040 | Schal | May 1981 | A |
4293409 | Riede et al. | Oct 1981 | A |
4310416 | Tanaka et al. | Jan 1982 | A |
4317725 | Kume et al. | Mar 1982 | A |
4342651 | Ahrens | Aug 1982 | A |
4476022 | Doll | Oct 1984 | A |
4486303 | Brous | Dec 1984 | A |
4500426 | Ishii et al. | Feb 1985 | A |
4508622 | Polaschegg | Apr 1985 | A |
4536201 | Brorsson et al. | Aug 1985 | A |
4624784 | Lefebvre | Nov 1986 | A |
4647748 | Glassman | Mar 1987 | A |
4661246 | Ash | Apr 1987 | A |
4689108 | Barry, Jr. et al. | Aug 1987 | A |
4756835 | Wilson | Jul 1988 | A |
4769134 | Allan et al. | Sep 1988 | A |
4770787 | Heath et al. | Sep 1988 | A |
4773991 | Aid | Sep 1988 | A |
4786411 | Benattar et al. | Nov 1988 | A |
4827430 | Aid et al. | May 1989 | A |
4869421 | Norris et al. | Sep 1989 | A |
4875619 | Anderson et al. | Oct 1989 | A |
4889635 | Chevallet | Dec 1989 | A |
4894164 | Polaschegg | Jan 1990 | A |
4923613 | Chevallet | May 1990 | A |
5087930 | Roy et al. | Feb 1992 | A |
5092836 | Polaschegg | Mar 1992 | A |
5094749 | Seita et al. | Mar 1992 | A |
5147605 | Tatsuno et al. | Sep 1992 | A |
5227049 | Chevallet et al. | Jul 1993 | A |
5232145 | Alley et al. | Aug 1993 | A |
5236476 | Klick | Aug 1993 | A |
5247434 | Peterson et al. | Sep 1993 | A |
5259961 | Eigendorf | Nov 1993 | A |
5312550 | Hester | May 1994 | A |
5313023 | Johnson | May 1994 | A |
5316676 | Drori | May 1994 | A |
5326476 | Grogan et al. | Jul 1994 | A |
5342326 | Peppel et al. | Aug 1994 | A |
5344392 | Senninger et al. | Sep 1994 | A |
5346472 | Keshaviah et al. | Sep 1994 | A |
5360395 | Utterberg | Nov 1994 | A |
5385623 | Diaz | Jan 1995 | A |
5394732 | Johnson et al. | Mar 1995 | A |
5395351 | Munsch | Mar 1995 | A |
5401238 | Pirazzoli | Mar 1995 | A |
5409612 | Maltais et al. | Apr 1995 | A |
5421208 | Packard et al. | Jun 1995 | A |
5439451 | Collinson et al. | Aug 1995 | A |
5469264 | Shigemori | Nov 1995 | A |
5472614 | Rossi | Dec 1995 | A |
5489385 | Raabe et al. | Feb 1996 | A |
5498253 | Aswad et al. | Mar 1996 | A |
5498338 | Kruger et al. | Mar 1996 | A |
5503624 | Roeher et al. | Apr 1996 | A |
5520640 | Utterberg | May 1996 | A |
5526357 | Jandrell | Jun 1996 | A |
5533996 | Murphey et al. | Jul 1996 | A |
5534328 | Ashmead et al. | Jul 1996 | A |
5536258 | Folden | Jul 1996 | A |
5580460 | Polaschegg | Dec 1996 | A |
5580523 | Bard | Dec 1996 | A |
5582600 | Loh | Dec 1996 | A |
5591016 | Kubota et al. | Jan 1997 | A |
5591344 | Kenley et al. | Jan 1997 | A |
5593581 | Lescoche | Jan 1997 | A |
5595712 | Harbster et al. | Jan 1997 | A |
5609770 | Zimmerman et al. | Mar 1997 | A |
5610645 | Moore et al. | Mar 1997 | A |
5611214 | Wegeng et al. | Mar 1997 | A |
5613663 | Schmidt et al. | Mar 1997 | A |
5615996 | Suzuki et al. | Apr 1997 | A |
5618268 | Raines et al. | Apr 1997 | A |
5618441 | Rosa et al. | Apr 1997 | A |
5620608 | Rosa et al. | Apr 1997 | A |
5623969 | Raines | Apr 1997 | A |
5624572 | Larson et al. | Apr 1997 | A |
5629871 | Love et al. | May 1997 | A |
5630804 | Imada et al. | May 1997 | A |
5643190 | Utterberg | Jul 1997 | A |
5647984 | Hovland et al. | Jul 1997 | A |
5648684 | Bertin et al. | Jul 1997 | A |
5650071 | Brugger et al. | Jul 1997 | A |
5662144 | Lo et al. | Sep 1997 | A |
5685835 | Brugger | Nov 1997 | A |
5689966 | Zess et al. | Nov 1997 | A |
5693008 | Brugger et al. | Dec 1997 | A |
5698916 | Eguchi | Dec 1997 | A |
5711883 | Folden et al. | Jan 1998 | A |
5713850 | Heilmann et al. | Feb 1998 | A |
5725773 | Polaschegg | Mar 1998 | A |
5743892 | Loh et al. | Apr 1998 | A |
5744031 | Bene | Apr 1998 | A |
5749226 | Bowman et al. | May 1998 | A |
5769985 | Kawakami et al. | Jun 1998 | A |
5779833 | Cawley et al. | Jul 1998 | A |
5782575 | Vincent et al. | Jul 1998 | A |
5788099 | Treu et al. | Aug 1998 | A |
5788851 | Kenley et al. | Aug 1998 | A |
5792367 | Mattisson et al. | Aug 1998 | A |
5811062 | Wegeng et al. | Sep 1998 | A |
5813235 | Peterson | Sep 1998 | A |
5851202 | Carlsson | Dec 1998 | A |
5858238 | Mcrea et al. | Jan 1999 | A |
5858239 | Kenley et al. | Jan 1999 | A |
5861555 | Hobro et al. | Jan 1999 | A |
5868930 | Kopf | Feb 1999 | A |
5879316 | Safar et al. | Mar 1999 | A |
5881774 | Utterberg | Mar 1999 | A |
5885456 | Charkoudian et al. | Mar 1999 | A |
5895368 | Utterberg | Apr 1999 | A |
5903211 | Flego et al. | May 1999 | A |
5910138 | Sperko et al. | Jun 1999 | A |
5914033 | Carlsson | Jun 1999 | A |
5921678 | Desai et al. | Jul 1999 | A |
5928177 | Brugger et al. | Jul 1999 | A |
5928180 | Krivitski et al. | Jul 1999 | A |
5932103 | Kenley et al. | Aug 1999 | A |
5932940 | Epstein et al. | Aug 1999 | A |
5938634 | Packard | Aug 1999 | A |
5938938 | Bosetto et al. | Aug 1999 | A |
5951870 | Utterberg | Sep 1999 | A |
5957898 | Jepson et al. | Sep 1999 | A |
5974867 | Forster et al. | Nov 1999 | A |
5976115 | Parris et al. | Nov 1999 | A |
5983947 | Utterberg | Nov 1999 | A |
5984903 | Nadal | Nov 1999 | A |
5993174 | Konishi | Nov 1999 | A |
6003556 | Brugger et al. | Dec 1999 | A |
6010623 | Schnell et al. | Jan 2000 | A |
6024276 | Hirata et al. | Feb 2000 | A |
6032926 | Fuchs | Mar 2000 | A |
6036680 | Horne et al. | Mar 2000 | A |
6039877 | Chevallet et al. | Mar 2000 | A |
6041801 | Gray et al. | Mar 2000 | A |
6044691 | Kenley et al. | Apr 2000 | A |
6048432 | Ecer | Apr 2000 | A |
6058934 | Sullivan | May 2000 | A |
6064797 | Crittendon et al. | May 2000 | A |
6066261 | Spickermann | May 2000 | A |
6071269 | Schnell et al. | Jun 2000 | A |
6074559 | Hahmann et al. | Jun 2000 | A |
6077443 | Goldau | Jun 2000 | A |
6082891 | Schubert et al. | Jul 2000 | A |
6100463 | Ladd et al. | Aug 2000 | A |
6109994 | Cho et al. | Aug 2000 | A |
6113785 | Miura et al. | Sep 2000 | A |
6117115 | Hill et al. | Sep 2000 | A |
6117123 | Barney et al. | Sep 2000 | A |
6121539 | Johnson et al. | Sep 2000 | A |
6123798 | Gandhi et al. | Sep 2000 | A |
6126723 | Drost et al. | Oct 2000 | A |
6126831 | Goldau et al. | Oct 2000 | A |
6129973 | Martin et al. | Oct 2000 | A |
6132616 | Twardowski et al. | Oct 2000 | A |
6139754 | Hartranft et al. | Oct 2000 | A |
6142008 | Cole et al. | Nov 2000 | A |
6143181 | Falkvall et al. | Nov 2000 | A |
6143247 | Sheppard et al. | Nov 2000 | A |
6148635 | Beebe et al. | Nov 2000 | A |
6153102 | Kenley et al. | Nov 2000 | A |
6165149 | Utterberg et al. | Dec 2000 | A |
6165161 | York et al. | Dec 2000 | A |
6167910 | Chow | Jan 2001 | B1 |
6187198 | Utterberg | Feb 2001 | B1 |
6187199 | Goldau | Feb 2001 | B1 |
6192596 | Bennett et al. | Feb 2001 | B1 |
6193462 | Kubota | Feb 2001 | B1 |
6202312 | Rando | Mar 2001 | B1 |
6203522 | Holmberg et al. | Mar 2001 | B1 |
6203535 | Barney et al. | Mar 2001 | B1 |
6212333 | Olk et al. | Apr 2001 | B1 |
6220299 | Arvidsson et al. | Apr 2001 | B1 |
6221040 | Kleinekofort | Apr 2001 | B1 |
6221064 | Nadal | Apr 2001 | B1 |
6223130 | Gray et al. | Apr 2001 | B1 |
6225497 | Becker et al. | May 2001 | B1 |
6234773 | Hill et al. | May 2001 | B1 |
6251279 | Peterson et al. | Jun 2001 | B1 |
6254567 | Treu et al. | Jul 2001 | B1 |
6254754 | Ross et al. | Jul 2001 | B1 |
6258276 | Mika et al. | Jul 2001 | B1 |
6261282 | Jepson et al. | Jul 2001 | B1 |
6277277 | Jacobi et al. | Aug 2001 | B1 |
6280406 | Dolecek et al. | Aug 2001 | B1 |
6284141 | Shaldon et al. | Sep 2001 | B1 |
6302653 | Bryant et al. | Oct 2001 | B1 |
6308721 | Bock et al. | Oct 2001 | B1 |
6309673 | Duponchelle et al. | Oct 2001 | B1 |
6322551 | Brugger | Nov 2001 | B1 |
6323662 | Ferri | Nov 2001 | B2 |
6325774 | Bene et al. | Dec 2001 | B1 |
6329139 | Nova et al. | Dec 2001 | B1 |
6331252 | El Sayyid et al. | Dec 2001 | B1 |
6334301 | Otsap et al. | Jan 2002 | B1 |
6343614 | Gray et al. | Feb 2002 | B1 |
6344033 | Jepson et al. | Feb 2002 | B1 |
6346084 | Schnell et al. | Feb 2002 | B1 |
6347711 | Goebel et al. | Feb 2002 | B1 |
6349170 | Fressinet et al. | Feb 2002 | B1 |
6350260 | Goebel et al. | Feb 2002 | B1 |
6355161 | Shah et al. | Mar 2002 | B1 |
6357332 | Vecchio | Mar 2002 | B1 |
6365041 | Hoadley | Apr 2002 | B1 |
6368505 | Grummert et al. | Apr 2002 | B1 |
6375871 | Bentsen et al. | Apr 2002 | B1 |
6382923 | Gray | May 2002 | B1 |
6387069 | Utterberg | May 2002 | B1 |
6395180 | Chioini et al. | May 2002 | B2 |
6415860 | Kelly et al. | Jul 2002 | B1 |
6416293 | Bouchard et al. | Jul 2002 | B1 |
6423022 | Roeher et al. | Jul 2002 | B1 |
6432309 | Fuke et al. | Aug 2002 | B1 |
6454736 | Ludt et al. | Sep 2002 | B1 |
6454942 | Shintani et al. | Sep 2002 | B1 |
6468056 | Murakoshi | Oct 2002 | B1 |
6477058 | Luebs et al. | Nov 2002 | B1 |
6481982 | Yokomichi | Nov 2002 | B1 |
6485263 | Bryant et al. | Nov 2002 | B1 |
6488842 | Nagaoka | Dec 2002 | B2 |
6488872 | Beebe et al. | Dec 2002 | B1 |
6503062 | Gray et al. | Jan 2003 | B1 |
6514225 | Utterberg et al. | Feb 2003 | B1 |
6514412 | Insley et al. | Feb 2003 | B1 |
6526357 | Soussan et al. | Feb 2003 | B1 |
6527728 | Zhang | Mar 2003 | B2 |
6530262 | Esser | Mar 2003 | B1 |
6536742 | Lotz et al. | Mar 2003 | B2 |
6537506 | Schwalbe et al. | Mar 2003 | B1 |
6544229 | Danby et al. | Apr 2003 | B1 |
6546998 | Oh et al. | Apr 2003 | B2 |
6554789 | Brugger et al. | Apr 2003 | B1 |
6572576 | Brugger et al. | Jun 2003 | B2 |
6572641 | Brugger et al. | Jun 2003 | B2 |
6575927 | Weitzel et al. | Jun 2003 | B1 |
6579241 | Roeher | Jun 2003 | B2 |
6579253 | Burbank et al. | Jun 2003 | B1 |
6581906 | Pott et al. | Jun 2003 | B2 |
6582385 | Burbank et al. | Jun 2003 | B2 |
6592558 | Quah | Jul 2003 | B2 |
6601432 | Ericson et al. | Aug 2003 | B1 |
6602424 | Krämer et al. | Aug 2003 | B1 |
6604908 | Bryant et al. | Aug 2003 | B1 |
6607644 | Apffel, Jr. | Aug 2003 | B1 |
6607697 | Müller | Aug 2003 | B1 |
6616877 | Close et al. | Sep 2003 | B2 |
6616909 | Tonkovich et al. | Sep 2003 | B1 |
6623860 | Hu et al. | Sep 2003 | B2 |
6630068 | Vinci | Oct 2003 | B1 |
6635226 | Tso et al. | Oct 2003 | B1 |
6640611 | Ericson et al. | Nov 2003 | B2 |
6649046 | Chevallet | Nov 2003 | B2 |
6649063 | Brugger et al. | Nov 2003 | B2 |
6652627 | Tonkovich et al. | Nov 2003 | B1 |
6653841 | Koerdt et al. | Nov 2003 | B1 |
6654660 | Singh et al. | Nov 2003 | B1 |
6666840 | Falkvall et al. | Dec 2003 | B1 |
6666909 | Tegrotenhuis et al. | Dec 2003 | B1 |
6672502 | Paul et al. | Jan 2004 | B1 |
6673311 | Sotoyama et al. | Jan 2004 | B1 |
6676621 | Menninger | Jan 2004 | B1 |
6676835 | O'Connor et al. | Jan 2004 | B2 |
6684710 | Chevallet et al. | Feb 2004 | B2 |
6685831 | Dönig et al. | Feb 2004 | B2 |
6686946 | Masuda et al. | Feb 2004 | B2 |
6688381 | Pence et al. | Feb 2004 | B2 |
6695807 | Bell et al. | Feb 2004 | B2 |
6716356 | Collins et al. | Apr 2004 | B2 |
6730233 | Pedrazzi | May 2004 | B2 |
6731216 | Ho et al. | May 2004 | B2 |
6733676 | Takai | May 2004 | B2 |
6736789 | Spickermann | May 2004 | B1 |
6738052 | Manke et al. | May 2004 | B1 |
6743193 | Brugger et al. | Jun 2004 | B2 |
6744038 | Wang et al. | Jun 2004 | B2 |
6746514 | Bedingfield et al. | Jun 2004 | B2 |
6749814 | Bergh et al. | Jun 2004 | B1 |
6767333 | Müller et al. | Jul 2004 | B1 |
6775577 | Crnkovich et al. | Aug 2004 | B2 |
6793831 | Paul et al. | Sep 2004 | B1 |
6797056 | David | Sep 2004 | B2 |
6804991 | Balschat et al. | Oct 2004 | B2 |
6806947 | Ekdahl et al. | Oct 2004 | B1 |
6811707 | Rovatti et al. | Nov 2004 | B2 |
6814547 | Childers et al. | Nov 2004 | B2 |
6814726 | Lauer | Nov 2004 | B1 |
6814859 | Koehler et al. | Nov 2004 | B2 |
6818179 | Edgson et al. | Nov 2004 | B1 |
6821432 | Metzner | Nov 2004 | B2 |
6827698 | Kleinekofort | Dec 2004 | B1 |
6830693 | Govoni et al. | Dec 2004 | B2 |
6838156 | Neyer et al. | Jan 2005 | B1 |
6852231 | Ivansons et al. | Feb 2005 | B2 |
6858137 | Hahmann et al. | Feb 2005 | B2 |
6863867 | Vanden Bussche et al. | Mar 2005 | B2 |
6868309 | Begelman | Mar 2005 | B1 |
6869538 | Yu et al. | Mar 2005 | B2 |
6871838 | Raines et al. | Mar 2005 | B2 |
6877713 | Gray et al. | Apr 2005 | B1 |
6878283 | Thompson | Apr 2005 | B2 |
6880034 | Manke et al. | Apr 2005 | B2 |
6881344 | Vasta et al. | Apr 2005 | B2 |
6889556 | Steger | May 2005 | B2 |
6892781 | Mcherron et al. | May 2005 | B2 |
6903332 | Weiss et al. | Jun 2005 | B2 |
6905479 | Bouchard et al. | Jun 2005 | B1 |
6911262 | Sallavanti et al. | Jun 2005 | B2 |
6913877 | Chaplen et al. | Jul 2005 | B1 |
6929751 | Bowman, Jr. et al. | Aug 2005 | B2 |
6936031 | Caleffi | Aug 2005 | B2 |
6939111 | Huitt et al. | Sep 2005 | B2 |
6939471 | Gross et al. | Sep 2005 | B2 |
6952963 | Delnevo | Oct 2005 | B2 |
6953323 | Childers et al. | Oct 2005 | B2 |
6955655 | Burbank et al. | Oct 2005 | B2 |
6967002 | Edgson et al. | Nov 2005 | B1 |
6974301 | Suzuki et al. | Dec 2005 | B2 |
6976964 | Chevallet et al. | Dec 2005 | B2 |
6979309 | Burbank et al. | Dec 2005 | B2 |
6981522 | O'Connor et al. | Jan 2006 | B2 |
6986428 | Hester et al. | Jan 2006 | B2 |
6989134 | Tonkovich et al. | Jan 2006 | B2 |
6994829 | Whyatt et al. | Feb 2006 | B2 |
7004924 | Brugger et al. | Feb 2006 | B1 |
7014705 | David | Mar 2006 | B2 |
7021148 | Kuhn et al. | Apr 2006 | B2 |
7022098 | Wariar et al. | Apr 2006 | B2 |
7029456 | Ware et al. | Apr 2006 | B2 |
7033498 | Wong | Apr 2006 | B2 |
7033539 | Krensky et al. | Apr 2006 | B2 |
7040142 | Burbank | May 2006 | B2 |
7044432 | Beden et al. | May 2006 | B2 |
7044927 | Mueller et al. | May 2006 | B2 |
7063512 | Haesloop et al. | Jun 2006 | B2 |
7070589 | Lolachi et al. | Jul 2006 | B2 |
7074191 | Bosetto et al. | Jul 2006 | B2 |
7087033 | Brugger et al. | Aug 2006 | B2 |
7087036 | Busby et al. | Aug 2006 | B2 |
7094345 | Gilbert et al. | Aug 2006 | B2 |
7112273 | Weigel et al. | Sep 2006 | B2 |
7114701 | Peppel | Oct 2006 | B2 |
7115206 | Chevallet et al. | Oct 2006 | B2 |
7115228 | Lundtveit et al. | Oct 2006 | B2 |
7118920 | Brophy et al. | Oct 2006 | B2 |
7121815 | Knuth et al. | Oct 2006 | B2 |
7122149 | Li et al. | Oct 2006 | B2 |
7122156 | Bergh et al. | Oct 2006 | B2 |
7125540 | Wegeng et al. | Oct 2006 | B1 |
7131956 | Pirazzoli et al. | Nov 2006 | B1 |
7147615 | Wariar et al. | Dec 2006 | B2 |
7150815 | Ashmead et al. | Dec 2006 | B2 |
7152469 | Milleker et al. | Dec 2006 | B2 |
7163531 | Seese et al. | Jan 2007 | B2 |
7166084 | Utterberg | Jan 2007 | B2 |
7168334 | Drott | Jan 2007 | B1 |
7170591 | Ohishi et al. | Jan 2007 | B2 |
7175697 | Neri | Feb 2007 | B2 |
7186342 | Pirazzoli et al. | Mar 2007 | B2 |
7188151 | Kumar et al. | Mar 2007 | B2 |
7211442 | Gilbert et al. | May 2007 | B2 |
7214312 | Brugger et al. | May 2007 | B2 |
7217108 | Herwig et al. | May 2007 | B2 |
7217364 | Lauer et al. | May 2007 | B2 |
7223262 | Brehm et al. | May 2007 | B2 |
7223338 | Duchamp et al. | May 2007 | B2 |
7232418 | Neri et al. | Jun 2007 | B2 |
7238164 | Childers et al. | Jul 2007 | B2 |
7247146 | Tonelli et al. | Jul 2007 | B2 |
7279134 | Chan et al. | Oct 2007 | B2 |
7291123 | Baraldi et al. | Nov 2007 | B2 |
7306197 | Parrino et al. | Dec 2007 | B2 |
7314061 | Peppel | Jan 2008 | B2 |
7316780 | Fendya et al. | Jan 2008 | B1 |
7337674 | Burbank et al. | Mar 2008 | B2 |
7341568 | Zhang | Mar 2008 | B2 |
7354426 | Young | Apr 2008 | B2 |
7355685 | Scibona et al. | Apr 2008 | B2 |
7378280 | Quake et al. | May 2008 | B2 |
7381195 | Mori et al. | Jun 2008 | B2 |
7393337 | Tonelli et al. | Jul 2008 | B2 |
7402249 | Ikeda | Jul 2008 | B2 |
7469716 | Parrino et al. | Dec 2008 | B2 |
7470265 | Brugger et al. | Dec 2008 | B2 |
7488301 | Beden et al. | Feb 2009 | B2 |
7488447 | Sternby | Feb 2009 | B2 |
7493824 | Brucksch et al. | Feb 2009 | B2 |
7494590 | Felding et al. | Feb 2009 | B2 |
7503908 | Bartholomew | Mar 2009 | B2 |
7507380 | Chang et al. | Mar 2009 | B2 |
7510545 | Peppel | Mar 2009 | B2 |
7517332 | Tonelli et al. | Apr 2009 | B2 |
7517387 | Chevallet et al. | Apr 2009 | B2 |
7520919 | Caleffi | Apr 2009 | B2 |
7537687 | Toyoda et al. | May 2009 | B2 |
7544300 | Brugger et al. | Jun 2009 | B2 |
7551043 | Nguyen et al. | Jun 2009 | B2 |
7559911 | Giannella | Jul 2009 | B2 |
7575562 | Oishi et al. | Aug 2009 | B2 |
7575564 | Childers | Aug 2009 | B2 |
7591449 | Raines et al. | Sep 2009 | B2 |
7603907 | Reiter et al. | Oct 2009 | B2 |
7615035 | Peppel | Nov 2009 | B2 |
7618531 | Sugioka et al. | Nov 2009 | B2 |
7622043 | Sawada et al. | Nov 2009 | B2 |
7632470 | Tabata et al. | Dec 2009 | B2 |
7647834 | O'Mahony et al. | Jan 2010 | B2 |
7648474 | Paolini et al. | Jan 2010 | B2 |
7648476 | Bock et al. | Jan 2010 | B2 |
7648792 | Kaschmitter et al. | Jan 2010 | B2 |
7656527 | Scarpaci | Feb 2010 | B2 |
7661294 | Dam | Feb 2010 | B2 |
7671974 | O'Mahony et al. | Mar 2010 | B2 |
7682328 | Han et al. | Mar 2010 | B2 |
7686778 | Burbank et al. | Mar 2010 | B2 |
7699992 | Sternby | Apr 2010 | B2 |
7708714 | Connell et al. | May 2010 | B2 |
7713226 | Ash et al. | May 2010 | B2 |
7726361 | Bartholomew | Jun 2010 | B2 |
7727220 | Wieslander et al. | Jun 2010 | B2 |
7744553 | Kelly et al. | Jun 2010 | B2 |
7749184 | Cavalcanti et al. | Jul 2010 | B2 |
7758082 | Weigel et al. | Jul 2010 | B2 |
7758547 | Tonelli et al. | Jul 2010 | B2 |
7771379 | Treu | Aug 2010 | B2 |
7771380 | Jönsson et al. | Aug 2010 | B2 |
7775986 | Roeher et al. | Aug 2010 | B2 |
7776219 | Brugger et al. | Aug 2010 | B2 |
7780848 | Kim et al. | Aug 2010 | B2 |
7788038 | Oshita et al. | Aug 2010 | B2 |
7790029 | Dannenmaier et al. | Sep 2010 | B2 |
7794141 | Perry et al. | Sep 2010 | B2 |
7794419 | Paolini et al. | Sep 2010 | B2 |
7801746 | Moll et al. | Sep 2010 | B2 |
7815852 | Sternby | Oct 2010 | B2 |
7824354 | Vinci et al. | Nov 2010 | B2 |
7873489 | Dolgos et al. | Jan 2011 | B2 |
7896831 | Sternby et al. | Mar 2011 | B2 |
7901579 | Brugger et al. | Mar 2011 | B2 |
7913751 | Zwittig | Mar 2011 | B2 |
7918993 | Harraway | Apr 2011 | B2 |
7922899 | Vasta et al. | Apr 2011 | B2 |
7955504 | Jovanovic et al. | Jun 2011 | B1 |
7968250 | Kaschmitter et al. | Jun 2011 | B2 |
8002727 | Brugger et al. | Aug 2011 | B2 |
8012114 | Daniel et al. | Sep 2011 | B2 |
8075509 | Molducci et al. | Dec 2011 | B2 |
8105265 | Demers et al. | Jan 2012 | B2 |
8128822 | Browning et al. | Mar 2012 | B2 |
8137554 | Jovanovic et al. | Mar 2012 | B2 |
8182440 | Cruz et al. | May 2012 | B2 |
8182691 | Stahl | May 2012 | B2 |
8190651 | Treu et al. | May 2012 | B2 |
8192387 | Brugger et al. | Jun 2012 | B2 |
8210049 | Brugger | Jul 2012 | B2 |
8235931 | Burbank et al. | Aug 2012 | B2 |
8236599 | Chang et al. | Aug 2012 | B2 |
8267881 | O'Mahony et al. | Sep 2012 | B2 |
8273245 | Jovanovic et al. | Sep 2012 | B2 |
8293113 | Jönsson et al. | Oct 2012 | B2 |
8293114 | Jönsson et al. | Oct 2012 | B2 |
8298427 | Ficheux et al. | Oct 2012 | B2 |
8323492 | Childers et al. | Dec 2012 | B2 |
8329030 | Childers et al. | Dec 2012 | B2 |
8343085 | Toyoda et al. | Jan 2013 | B2 |
8394046 | Nuernberger et al. | Mar 2013 | B2 |
8414182 | Paul et al. | Apr 2013 | B2 |
8419945 | Browning et al. | Apr 2013 | B2 |
8449487 | Hovland et al. | May 2013 | B2 |
8460228 | Burbank et al. | Jun 2013 | B2 |
8475398 | O'Mahony | Jul 2013 | B2 |
8491518 | Schnell et al. | Jul 2013 | B2 |
8496824 | Remkes et al. | Jul 2013 | B2 |
8501009 | Peterson et al. | Aug 2013 | B2 |
8506536 | Schnell | Aug 2013 | B2 |
8512553 | Cicchello et al. | Aug 2013 | B2 |
8512554 | Yu et al. | Aug 2013 | B2 |
8524086 | Peterson et al. | Sep 2013 | B2 |
8529491 | Beiriger | Sep 2013 | B2 |
8603020 | Roger et al. | Dec 2013 | B2 |
8608658 | Burbank et al. | Dec 2013 | B2 |
8647290 | Masala et al. | Feb 2014 | B2 |
8679348 | Burbank et al. | Mar 2014 | B2 |
8685251 | Smejtek et al. | Apr 2014 | B2 |
8753515 | Curtis et al. | Jun 2014 | B2 |
8801922 | Wrazel et al. | Aug 2014 | B2 |
8840581 | McGill et al. | Sep 2014 | B2 |
9024746 | Burbank et al. | May 2015 | B2 |
9097370 | Schnell et al. | Aug 2015 | B2 |
9138687 | Peterson et al. | Sep 2015 | B2 |
9328969 | Wrazel et al. | May 2016 | B2 |
9402945 | Hogard et al. | Aug 2016 | B2 |
20020023879 | Hadden | Feb 2002 | A1 |
20020032398 | Steele et al. | Mar 2002 | A1 |
20020108859 | Wang et al. | Aug 2002 | A1 |
20020108869 | Savtchenko | Aug 2002 | A1 |
20020115200 | Zou et al. | Aug 2002 | A1 |
20020162784 | Kohlheb et al. | Nov 2002 | A1 |
20020187069 | Levin et al. | Dec 2002 | A1 |
20030010717 | Brugger et al. | Jan 2003 | A1 |
20030039169 | Ehrfeld et al. | Feb 2003 | A1 |
20030052429 | Vigna et al. | Mar 2003 | A1 |
20030082066 | Hajaligol et al. | May 2003 | A1 |
20030138349 | Robinson et al. | Jul 2003 | A1 |
20030156991 | Halas et al. | Aug 2003 | A1 |
20030163077 | Kim et al. | Aug 2003 | A1 |
20030183345 | Soberay | Oct 2003 | A1 |
20030220598 | Busby et al. | Nov 2003 | A1 |
20040004589 | Shih | Jan 2004 | A1 |
20040008370 | Keane et al. | Jan 2004 | A1 |
20040012122 | Nagaoka et al. | Jan 2004 | A1 |
20040016700 | Kellam et al. | Jan 2004 | A1 |
20040020286 | Blakley et al. | Feb 2004 | A1 |
20040022691 | Allen et al. | Feb 2004 | A1 |
20040035452 | Ma | Feb 2004 | A1 |
20040035462 | McCarty et al. | Feb 2004 | A1 |
20040072278 | Chou et al. | Apr 2004 | A1 |
20040084370 | Singh et al. | May 2004 | A1 |
20040084371 | Kellam et al. | May 2004 | A1 |
20040086427 | Childers et al. | May 2004 | A1 |
20040125689 | Ehrfeld et al. | Jul 2004 | A1 |
20040157096 | Peterson | Aug 2004 | A1 |
20040158189 | Tonelli et al. | Aug 2004 | A1 |
20040208751 | Lazar et al. | Oct 2004 | A1 |
20040215129 | Edgson et al. | Oct 2004 | A1 |
20040256230 | Yager et al. | Dec 2004 | A1 |
20050006296 | Sullivan et al. | Jan 2005 | A1 |
20050007748 | Callahan et al. | Jan 2005 | A1 |
20050070837 | Ferrarini et al. | Mar 2005 | A1 |
20050074834 | Chaplen et al. | Apr 2005 | A1 |
20050082225 | Kreymann | Apr 2005 | A1 |
20050126211 | Drost et al. | Jun 2005 | A1 |
20050129580 | Swinehart et al. | Jun 2005 | A1 |
20050131332 | Kelly et al. | Jun 2005 | A1 |
20050145497 | Gilbert et al. | Jul 2005 | A1 |
20050179748 | Malik et al. | Aug 2005 | A1 |
20050202557 | Borenstein et al. | Sep 2005 | A1 |
20060079698 | Joshi et al. | Apr 2006 | A1 |
20060157413 | Bene et al. | Jul 2006 | A1 |
20060200064 | Gross et al. | Sep 2006 | A1 |
20060266692 | Foster et al. | Nov 2006 | A1 |
20070020400 | Chang | Jan 2007 | A1 |
20070029365 | Paul et al. | Feb 2007 | A1 |
20070119771 | Schukar et al. | May 2007 | A1 |
20070125489 | Paul et al. | Jun 2007 | A1 |
20070128707 | Rorrer et al. | Jun 2007 | A1 |
20070131403 | Vetrovec et al. | Jun 2007 | A1 |
20070158249 | Ash | Jul 2007 | A1 |
20070158268 | Decomo | Jul 2007 | A1 |
20070184576 | Chang et al. | Aug 2007 | A1 |
20070215644 | Otis et al. | Sep 2007 | A1 |
20070278155 | Lo et al. | Dec 2007 | A1 |
20070295651 | Martinez et al. | Dec 2007 | A1 |
20080006040 | Peterson et al. | Jan 2008 | A1 |
20080009780 | Leonard et al. | Jan 2008 | A1 |
20080097274 | Neri et al. | Apr 2008 | A1 |
20080108122 | Paul et al. | May 2008 | A1 |
20080108930 | Weitzel et al. | May 2008 | A1 |
20080149563 | Ash | Jun 2008 | A1 |
20080196725 | Mele | Aug 2008 | A1 |
20080200858 | Ichiishi et al. | Aug 2008 | A1 |
20080296226 | Gotch | Dec 2008 | A1 |
20090008331 | Wilt et al. | Jan 2009 | A1 |
20090012452 | Slepicka et al. | Jan 2009 | A1 |
20090038393 | Chaung et al. | Feb 2009 | A1 |
20090087326 | Voltenburg et al. | Apr 2009 | A1 |
20090092526 | Miller | Apr 2009 | A1 |
20090095679 | Demers et al. | Apr 2009 | A1 |
20090101549 | Kamen et al. | Apr 2009 | A1 |
20090101576 | Rohde et al. | Apr 2009 | A1 |
20090114595 | Wallenas et al. | May 2009 | A1 |
20090124963 | Hogard et al. | May 2009 | A1 |
20090165366 | Jovanovic et al. | Jul 2009 | A1 |
20090211977 | Miller | Aug 2009 | A1 |
20090306573 | Gagner et al. | Dec 2009 | A1 |
20090309835 | Levin et al. | Dec 2009 | A1 |
20100018923 | Rohde et al. | Jan 2010 | A1 |
20100022934 | Hogard | Jan 2010 | A1 |
20100051552 | Rohde et al. | Mar 2010 | A1 |
20100078385 | Kawarabata et al. | Apr 2010 | A1 |
20100192686 | Kamen et al. | Aug 2010 | A1 |
20100271296 | Kopychev et al. | Oct 2010 | A1 |
20100292627 | Caleffi et al. | Nov 2010 | A1 |
20100292657 | Fontanazzi et al. | Nov 2010 | A1 |
20100321046 | Randall et al. | Dec 2010 | A1 |
20100326914 | Drost et al. | Dec 2010 | A1 |
20110005986 | Kelly et al. | Jan 2011 | A1 |
20110105979 | Schlaeper et al. | May 2011 | A1 |
20110106466 | Furmanski et al. | May 2011 | A1 |
20110132841 | Rohde et al. | Jun 2011 | A1 |
20110186517 | Hedmann et al. | Aug 2011 | A1 |
20110189048 | Curtis et al. | Aug 2011 | A1 |
20110257579 | Rossi et al. | Oct 2011 | A1 |
20110295175 | Felder et al. | Dec 2011 | A1 |
20120029937 | Neftel et al. | Feb 2012 | A1 |
20120065581 | Childers et al. | Mar 2012 | A1 |
20120103902 | Childers et al. | May 2012 | A1 |
20120138533 | Curtis et al. | Jun 2012 | A1 |
20120292246 | Jovanovic et al. | Nov 2012 | A1 |
20120318740 | Ekdahl et al. | Dec 2012 | A1 |
20130018301 | Weaver et al. | Jan 2013 | A1 |
20130020237 | Wilt et al. | Jan 2013 | A1 |
20130056419 | Curtis | Mar 2013 | A1 |
20130186829 | Callan et al. | Jul 2013 | A1 |
20140021111 | Roger et al. | Jan 2014 | A1 |
20140069861 | Browning et al. | Mar 2014 | A1 |
20140209540 | Smejtek et al. | Jul 2014 | A1 |
20140291243 | Curtis et al. | Oct 2014 | A1 |
20140299545 | Wrazel et al. | Oct 2014 | A1 |
20150314055 | Hogard et al. | Nov 2015 | A1 |
20150328386 | Peterson et al. | Nov 2015 | A1 |
20150343128 | Hogard et al. | Dec 2015 | A1 |
20150343131 | Hogard et al. | Dec 2015 | A1 |
20150343132 | Hogard et al. | Dec 2015 | A1 |
20150343133 | Hogard et al. | Dec 2015 | A1 |
20150354906 | Miller | Dec 2015 | A1 |
20160082172 | Miller et al. | Mar 2016 | A1 |
Number | Date | Country |
---|---|---|
200951223 | Sep 2007 | CN |
8702995 | Jun 1987 | DE |
69217519 | Jun 1997 | DE |
0165751 | Dec 1985 | EP |
0324922 | Jul 1989 | EP |
0679100 | Nov 1995 | EP |
0796997 | Sep 1997 | EP |
0547025 | Jun 2002 | EP |
1289738 | Sep 1972 | GB |
59-58002 | Apr 1984 | JP |
60-143803 | Jul 1985 | JP |
2002143298 | May 2002 | JP |
2007268490 | Oct 2007 | JP |
2007529707 | Oct 2007 | JP |
WO0016916 | Mar 2000 | WO |
WO0025843 | May 2000 | WO |
WO0240874 | May 2002 | WO |
WO02076529 | Oct 2002 | WO |
WO03076661 | Sep 2003 | WO |
WO2006039293 | Apr 2006 | WO |
WO2007089855 | Aug 2007 | WO |
WO2008027967 | Mar 2008 | WO |
WO2008106191 | Sep 2008 | WO |
WO2010027435 | Mar 2010 | WO |
WO2010062698 | Jun 2010 | WO |
WO2010085764 | Jul 2010 | WO |
Entry |
---|
Allis et al., “Chapter 16: Nanostructural Architectures from Molecular Building Blocks,” in Handbook of Nanoscience, Engineering, and Technology, 1st Edition (Electrical Engineering Handbook), CRC Press LLC, Boca Raton, FL, Chapter 16 (70 pgs.), Oct. 2002. |
Anglés et al., “Plasticized starch/Tunicin Whiskers Nanocomposite Materials. 2. Mechanical behavior,” Macromolecules, 34, pp. 2921-2931, Mar. 2001. |
California Energy Commission; Development of Supported Polymeric Liquid Membrane Technology for Aqueous MTBE Mitigation, EPRI, Palo Alto, CA, California Energy Commission, Sacramento, CA: Doc. No. 1006577; 70 pgs.; Jul. 2002. |
Demura et al., “Ductile Thin Foil of Ni3Al,” Mechanical Properties of Structural Films, ASTM International Nov. 2000 Symposium (Orlando, FL), pp. 248-261, published Oct. 1, 2001. |
Favier et al.; Nanocomposite materials from latex and cellulose whiskers; Polymers for Advanced Technologies; 6; pp. 351-355; Jan. 1995. |
Federal Energy Technology Center, “Technology Development Through Industrial Partnerships,” (Tech. Dev. Data Sheet), 12 pgs., Sep. 1998. |
Grunert et al., “Progress in the Development of Cellulose Reinforced Nanocomposites,” PMSE Preprints 2000, 82, 232, 2 pgs., Mar. 2000. |
Haas, “Further development of MMW and SMMW platelet feed horn arrays,” Astron. Soc. Pac. Conf. Ser., vol. 75, pp. 99-105, Multi-Feed Systems for Radio Telescopes, Workshop held in Tucson, Arizona, May 16-18, 1994. |
Introtek International; Drip chamber liquid level sensor (sales literature); 2 pages; retrieved from the internet (http://www.introtek.com/PDFs/l/DDS-14.0—DripDetectSensor.pdf); © Jan. 1, 2009. |
Koeneman et al., “Feasibility of Micro Power Supplies for MEMS,” (pre-publication copy) J. MicroElectoMechanical Sys., 6(4), pp. 355-362, Dec. 1997. |
Morin et al., “Nanocomposites of Chitin Whiskers from Riftia Tubes and Poly (caprolactone),” Macromolecules, vol. 35, pp. 2190-2199, Feb. 2002. |
Nakamura et al., “Research on Pressure Welding Conditions of Various Work Metals (Effects of Contact Pressure, Surface Expansion Ratio and Temperature),” JSME International Journal, Series III 31(3), 612-617, Sep. 1988. |
Nakao et al., “Diffusion Bonding of Intermetallic Compound TiAl,” ISIJ International, 31(10), 1260-1266, Oct. 1991. |
Oddy et al., “Electrokinetic Instability Micromixing,” Anal. Chem., 73(24), pp. 5822-5832, Dec. 2001. |
Omega Engineering Inc.; Load Cell (definition, information); 3 pgs; retrieved from the internet on Jun. 17, 2015 (http://www.omega.com/prodinfo/LoadCells.html). |
Orts et al., “Effect of Fiber Source on Cellulose Reinforced Polymer Nanocomposites,” ANTEC 2004: Conference Proceedings, 62nd Annual Tech. Conference; Chicago, IL, pp. 2427-2431, May 2004. |
Paillet et al., “Chitin Whisker Reinforced Thermoplastic Nanocomposites,” Macromolecules, vol. 34, No. 19, pp. 6527-6530, Sep. 2001. |
Paul et al., “Microlamination for Microtechnology-based Energy, Chemical, and Biological Systems,” ASME IMECE, ASE vol. 39, pp. 45-52, Nashville, Tennessee, Nov. 15-20, 1999. |
Pluess, “Application of Controlled Thermal Expansion in Diffusion Bonding for the High-Volume Microlamination of MECS Devices,” Thesis (MS), Oregon State University, 193 pgs., Sep. 2004. |
Porter et al.; Cost drivers in microlamination based on a high volume production system design; ASME 2002 Conf. Proc.; New Orleans, Louisiana; pp. 267-274; Nov. 17-22, 2002. |
Sharma et al., “The Application of Surface Mount Technology to Multi-Scale Process Intensification,” ASPE, pp. 1-4, Oct. 2003. |
Stroock et al., “Chaotic Mixer for Microchannels,” Science, 295, pp. 647-651, Jan. 2002. |
Thorsen et al.; Microfluidic Large-Scale Integration; Science; 298; pp. 580-584; Oct. 18, 2002. |
Wegeng et al., “Chemical system miniaturization,” Proceedings of the AIChE Spring National Meeting, pp. 1-13, Feb. 1996. |
Number | Date | Country | |
---|---|---|---|
20160339162 A1 | Nov 2016 | US |
Number | Date | Country | |
---|---|---|---|
61267043 | Dec 2009 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 14305952 | Jun 2014 | US |
Child | 15225712 | US | |
Parent | 12795498 | Jun 2010 | US |
Child | 14305952 | US |